1. U.S. Department of Health, Food and Drug Administration. Modified Release Solid Oral Dosage Form Guidance: Scale-up and Postapproval Changes: Chemistry, Manufacturing and Controls, In vitro Dissolution Testing and In vivo Bioequivalence Documentation. U.S. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), September, 1997.
2. U.S. Department of Health, Food and Drug Administration. Guidance for the Industry: Extended Release Solid Oral Dosage Forms: Development, Evaluation and Application of In vitro/In vivo Correlations. U.S. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), September 1997.
3. High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms
4. Optimization of Sustained-release Diltiazem Formulations in Man by use of an In-vitro/In-vivo Correlation